Journal of Clinical Oncology

Log In
assignment_turned_inSubmit
mail_outlineE-Alerts
add_shopping_cartSubscribe

OpenAthens/Shibboleth »

Enter words / phrases / DOI / ISBN / authors / keywords / etc.
Advanced Search
  • Newest Articles
  • Issues
    • Current Issue
    • Past Issues
  • Special Content
    • ASCO Guidelines
    • Special Series
    • JCO Podcasts
    • Cancer Stories Podcast
    • Meeting Abstracts
    • Oncology Grand Rounds
    • Understanding the Pathway
  • Authors
    • Author Center
    • Open Access Terms
    • Preparing a Manuscript
      • Determine My Article Type
      • Format My Manuscript
      • Submit My Manuscript
      • Contact Editorial
    • What To Expect
      • Peer Review Process
      • My Article Was Accepted
    • Policies and Guidelines
      • Journal Policies
      • Embargo Policy
      • Author Promotion Toolkit
    • Resources
      • From the Editors
      • Author FAQ
      • Professional English and Academic Editing Support
      • Rapid Technical Review
    • Submit to JCO
  • Subscribers
    • Subscriber Center
    • Manage Subscription
    • Renew Subscription
    • View/Change User Info
    • Institutions and Librarians
    • Subscribe to this Journal
    • Email Alerts
    • Subscriber FAQ
  • About
    • About JCO
    • Editorial Roster
    • Permissions
    • Reprints
    • Advertising
    • Become a Reviewer
    • Contact Us
  • ASCO Publications
    • Journal of Clinical Oncology
    • JCO Oncology Practice
    • JCO Global Oncology
    • JCO Clinical Cancer Informatics
    • JCO Precision Oncology
    • ASCO Publications Home
  • Career Center
  • COVID-19
Follow @ASCO_Pubs on Twitter
Log In

NEWEST CONTENT

  • ORIGINAL REPORTS
    Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
    Chi et al.
    April 29, 2021
  • CORRESPONDENCE
    Adjuvant Hormone Therapy After Prostate Radiation: Is This Data Torture?
    Sundar et al.
    April 29, 2021
  • CORRESPONDENCE
    Timing of ADT in Radiotherapy of Prostate Cancer
    Höcht et al.
    April 29, 2021
  • CORRESPONDENCE
    Reply to S. Sundar et al and S. Höcht et al
    Spratt et al.
    April 29, 2021
  • ORIGINAL REPORTS
    Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma
    Alig et al.
    April 28, 2021
More Articles »

FEATURED CONTENT

RAPID COMMUNICATIONS

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial
Loibl et al. | April 1, 2021

ASCO SPECIAL ARTICLES

Management of Dyspnea in Advanced Cancer: ASCO Guideline
Hui et al. | February 22, 2021

Dr. Jonathan Friedberg

NEWS

Jonathan W. Friedberg Named Next Editor-in-Chief of the Journal of Clinical Oncology
July 27, 2020

CURRENT ISSUE | May 1, 2021

Publication Cover

ASCO SPECIAL ARTICLE

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Korde et al.

ORIGINAL REPORTS

T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects
Vasileiou et al.

ORIGINAL REPORTS

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
Garcia-Manero et al.

ORIGINAL REPORTS

Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932
Angiolillo et al.

ORIGINAL REPORTS

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Piccart et al.

ORIGINAL REPORTS

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
Prat et al.

ORIGINAL REPORTS

HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study
Haffner et al.

UNDERSTANDING THE PATHWAY

Expanding the Toolbox of Adoptive Cell Immunotherapy
Hossain et al.
More Articles »

SPONSORED CONTENT

Sponsored by Puma Biotechnology
Adjuvant Therapy in HER2-Positive, Hormone Receptor–Positive Breast Cancer

JCO PODCASTS

Listen to Cancer Stories: The Art of Oncology podcast series »

MOST READ

 (Last 60 days)
  • Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
    Key et al.
  • Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
    Reck et al.
  • Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
    Hutchings et al.
  • Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial
    Loibl et al.
More Articles »

ASCO Career Center

Quick Links

Content

Newest Articles
Archive
Meeting Abstracts

Journal Information

About
Editorial Roster
Contact Us
Permissions

Resources

Authors
Reviewers
Subscribers
Institutions
Advertisers

Submit Your Manuscript

Subscribe to this Journal

ASCO Family of Sites

Journals

Journal of Clinical Oncology
JCO Oncology Practice
JCO Global Oncology
JCO Clinical Cancer Informatics
JCO Precision Oncology

Publications

ASCO Educational Book
ASCO Daily News
ASCO Connection
The ASCO Post
JCO OP DAiS

Education

ASCO eLearning
ASCO Meetings
Cancer.Net

Other Sites

ASCO.org
ASCO Author Services
ASCO Career Center
CancerLinQ
Conquer Cancer Foundation
TAPUR Study

  • ASCO
    American Society of Clinical Oncology
  • 2318 Mill Road, Suite 800, Alexandria, VA 22314
  • © 2021 American Society of Clinical Oncology

Facebook Twitter LinkedIn YouTube

Terms of Use | Privacy Policy | Cookies